Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617765 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL135107 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL29676707 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL335622 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL29350839 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL16345210 | 0.98 | TAAR1 (0.55) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL12495550 | 0.98 | TAAR1 (0.55) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL10781087 | 0.85 | AOC3 (0.54) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL10781776 | 0.85 | AOC3 (0.54) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL8204131 | 0.84 | TAAR1 (0.53) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387385-A1 | TREATMENT FOR GLOMERULAR DISEASES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-12-25 | — | — | US | claimed |
| EP-4565233-A1 | TREATMENT FOR APLASTIC ANEMIA (AA) | Zydus Lifesciences Limited (IN) | 2025-06-11 | — | — | EP | claimed |
| EP-4539934-A1 | TREATMENT FOR GLOMERULAR DISEASES | Zydus Lifesciences Limited (IN) | 2025-04-23 | — | — | EP | claimed |
| US-20250078176-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| CN-119162143-A | High-conversion rate transaminase mutant, encoding gene and application thereof | 浙江大学 | 2024-12-20 | — | — | CN | claimed |
| CN-118435582-A | Environmental attributes of nitrogen-containing chemicals | 巴斯夫欧洲公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240173314-A1 | TREATMENT OF SICKLE CELL ANAEMIA | ZYDUS LIFESCIENCES LTD. (IN) | 2024-05-30 | — | — | US | claimed |
| WO-2024028744-A1 | TREATMENT FOR APLASTIC ANEMIA (AA) | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-02-08 | — | — | WO | claimed |
| WO-2023248193-A1 | TREATMENT FOR GLOMERULAR DISEASES | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-12-28 | — | — | WO | claimed |
| CN-114804989-B | Purification method and racemization recycling of rivastigmine key chiral intermediate | 华中科技大学 | 2023-12-26 | — | — | CN | claimed |
| WO-2010063774-A1 | NOVEL 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | WO | claimed |
| WO-2009147687-A2 | AN IMPROVED PROCESS FOR THE SEPARATION OF ENANTIOMERICALLY PURE COMPOUNDS | SHODHANA LABORATORIES LIMITED (IN) | 2009-12-10 | — | — | WO | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| US-20080255383-A1 | PREPARATION OF RIVASTIGMINE AND ITS SALTS | DR. REDDY'S LABORATORIES, INC. | 2008-10-16 | — | — | US | claimed |
| EP-1980552-A2 | A process for the preparation of rivastigmine or a salt thereof | Dr. Reddy's Laboratories Ltd. (IN) | 2008-10-15 | — | — | EP | claimed |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2006-10-12 | — | — | US | claimed |
| EP-1659120-A1 | 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GlaxoSmithKline S.p.A. (IT) | 2006-05-24 | — | — | EP | claimed |
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | TAAR1 2524/4885AOC3 3117/4885ALDH1A1 1460/4885 |
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | HRH4, HRH2, HRH3 | TAAR1 659/4885AOC3 1399/4885ALDH1A1 3625/4885 |
| US-20080255383-A1 | PREPARATION OF RIVASTIGMINE AND ITS SALTS | ACHE, EHMT1, BCHE | TAAR1 3130/4885AOC3 957/4885ALDH1A1 1784/4885 |
| US-20250387385-A1 | TREATMENT FOR GLOMERULAR DISEASES | SSB, GRN, ALB | TAAR1 4597/4885AOC3 1505/4885ALDH1A1 3041/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | TAAR1 2307/4885AOC3 2448/4885ALDH1A1 1428/4885 |
| US-20240173314-A1 | TREATMENT OF SICKLE CELL ANAEMIA | HBG1, HBB, HBG2 | TAAR1 4317/4885AOC3 2123/4885ALDH1A1 240/4885 |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | KCNK3, KCNJ2, KCNK2 | TAAR1 916/4885AOC3 2019/4885ALDH1A1 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.